Coenzyme Q10 in patients undergoing CABG: Effect of statins and nutritional supplementation

Keith, Mary; Mazer, C. David; Mikhail, Philopatir; Jeejeebhoy, Farida M.; Briet, F.; Errett, Lee

doi:10.1016/j.numecd.2006.09.011

Cited by 9 publications

(11 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The following types of research reports were reviewed: one double‐blind RCT (Caso, Kelly, McNurlan, & Lawson, ); one single center, randomized, parallel‐group study with three arms (Berthold et al, ); two single blind RCTs (Keith et al, ; Young et al, ); one prospective analysis (Langsjoen, Langsjoen, Langsjoen, & Lucas, ); one open study (Lamperti et al, ); and two studies in which design was not specified (Chu et al, ; Mabuchi et al, ).…”

Section: Resultsmentioning

confidence: 99%

“…Keith et al () conducted an RCT with 39 patients where 24 patients were on statin therapy for an unspecified length of time and 15 were not taking statins. Subjects in the group were randomized to either a placebo or a twice daily tetra pack of liquid nutritional supplement while continuing their regular statin dose.…”

Section: Resultsmentioning

confidence: 99%

“…Upon initiation of the study, plasma levels of CoQ10 showed a slight decrease for the statin group compared to the nonstatin group with a median of 0.57 μg/mL vs. 0.78 μg/mL, respectively, with a p ‐value of .07. Supplementation after 4 weeks showed plasma levels of CoQ10 significantly increased ( p = .001) in comparison with those who received the placebo, 1.8 vs. 0.8, respectively (Keith et al, ). Keith et al () also studied the concentrations of cardiac tissue CoQ10 of the same patients.…”

Section: Resultsmentioning

confidence: 99%

“…Supplementation after 4 weeks showed plasma levels of CoQ10 significantly increased ( p = .001) in comparison with those who received the placebo, 1.8 vs. 0.8, respectively (Keith et al, ). Keith et al () also studied the concentrations of cardiac tissue CoQ10 of the same patients. Cardiac tissue concentration of CoQ10 also improved with supplementation from 87.3 to 120.5 ( p = .04).…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Statins’ effect on plasma levels of Coenzyme Q10 and improvement in myopathy with supplementation

Littlefield

Beckstrand

Luthy

2014

Journal of the American Association of Nurse Practitioners

View full text Add to dashboard Cite

PurposeHeart disease is the leading cause of death in the United States. HMG‐CoA reductase inhibitors, or statins, are medications at the forefront of the battle against cardiovascular disease. Despite their effectiveness, patient compliance with statins has lagged because of medication cost and adverse effects, namely myopathy. Myopathy is the most common side effect of statin use. The purpose of this review is to report plasma levels of CoQ10 in patients taking statins and then to determine the benefit of Coenzyme Q10 (CoQ10) supplementation on statin‐related myopathy as evidenced by symptomatic improvement and increase in serum levels of CoQ10. Data sourcesCINAHL, Medline, Health Source: Nursing/Academic Edition, and Cochrane Library. ConclusionsEvidence from this review suggests that studies showed a significant relationship between statin intake and decreased serum levels of CoQ10. A few studies showed a benefit in symptoms of myalgia or improvement of serum levels of CoQ10 with supplementation. One study showed no benefit of CoQ10 supplementation when taken with statins. There were no risks of supplementation reported in any of the studies. Implications for PracticeCoQ10 supplementation might benefit those patients suffering from statin‐induced myopathy as evidenced by the results of these studies. Supplementation of CoQ10 at a dose of between 30 and 200 mg daily has shown to have beneficial effects on statin myopathy with no noted side effects. Further research is necessary.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Statins’ effect on plasma levels of Coenzyme Q10 and improvement in myopathy with supplementation

Littlefield

Beckstrand

Luthy

2014

Journal of the American Association of Nurse Practitioners

View full text Add to dashboard Cite

show abstract

“…The relationship between plasma and tissue levels of CoQ10 is not fully understood. A small study of 40 patients by Keith et al did show that CoQ10 levels in cardiac biopsy specimens were higher in patients who had received 4 weeks of supplementation compared to those who had not, and were associated with an increase in plasma CoQ10 [36]. Levels in chest wall muscle were not different between supplement and no supplement groups, and pre-supplement biopsy levels were not available.…”

Section: Co Enzyme Q10 Interactionmentioning

confidence: 97%

Statins in Heart Failure—Where Do We Stand?

Lyons¹,

McVeigh²,

Harbinson³

2010

Cardiovasc Drugs Ther

View full text Add to dashboard Cite

HMG Co-A reductase inhibitors (statins) are a group of drugs which lower cholesterol by inhibiting the conversion of HMG Co-A to mevalonate early in the cholesterol synthetic pathway. They are used in the primary and secondary prevention of cardiovascular events in patients deemed to be at increased risk and their benefit in patients with ischaemic heart disease is well supported. Their use in patients with heart failure (HF) however, is controversial. Evidence from observational and mechanistic studies suggests that statins should benefit patients with HF. However, larger randomised controlled trials have failed to demonstrate these expected benefits. The aim of this review article is to summarise the data from trials of statin use in patients with HF and attempt to explain the apparent conflict between recent placebo controlled trials and earlier observational and mechanistic studies.

show abstract